DelveInsight’s, “Diabetic Neuropathic Pain- Pipeline Insight 2024” report provides comprehensive insights about 10+ companies and 12+ pipeline drugs in Diabetic Neuropathic Pain pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Explore our latest breakthroughs in Diabetic Neuropathic Pain Research. Learn more about our innovative pipeline today! @ Diabetic Neuropathic Pain Pipeline Outlook
Key Takeaways from the Diabetic Neuropathic Pain Pipeline Report
- In October 2024:- Lexicon Pharmaceuticals- A Phase 2b, Dose-ranging, Randomized, Double-blind, PlacebO-controlled, Parallel-GRoup, MulticEnter Study in PatientS with Diabetic Peripheral Neuropathic Pain (PROGRESS).
- In October 2024:- Vertex Pharmaceuticals Incorporated- A Phase 3, Randomized, Double-blind, Placebo- and Active-Controlled Study of the Efficacy and Safety of Suzetrigine in Subjects With Pain Associated With Diabetic Peripheral Neuropathy. The purpose of this study is to evaluate the efficacy, safety, and tolerability of Suzetrigine (SUZ) in participants with pain associated with diabetic peripheral neuropathy (DPN).
- In October 2024:- Eli Lilly and Company- A Phase 2, Randomized, Double-Blind, Placebo Controlled, Dose-Finding Study Evaluating LY3848575 in Chronic Neuropathic Pain Associated With Distal Sensory Polyneuropathy. The purpose of this study is to evaluate how safe and how well a treatment works compared to placebo for people with nerve pain that begins in their feet and moves up the leg to just below the knee.
- DelveInsight’s Diabetic Neuropathic Pain pipeline report depicts a robust space with 10+ active players working to develop 12+ pipeline therapies for Diabetic Neuropathic Pain treatment.
- The leading Diabetic Neuropathic Pain Companies such as Lexicon Pharmaceuticals, Biogen, JMackem, Zhejiang Hanmai Pharmaceutical Technology Co., Ltd., Eli Lilly and Company, Lateral Pharma Pty Ltd, Tris Pharma, Inc., and others.
- Promising Diabetic Neuropathic Pain Therapies such as Incobotulinumtoxin-A 100 UNIT Injection, LX9211, JMKX000623, Pregabalin, RTA 901, HSK16149 20mg BID, and others.
Stay informed about the cutting-edge advancements in Diabetic Neuropathic Pain Treatments. Download for updates and be a part of the revolution in cancer care @ Diabetic Neuropathic Pain Clinical Trials Assessment
Diabetic Neuropathic Pain Emerging Drugs Profile
- Cemdomespib: Biogen
Cemdomespib is a is a highly potent and selective, oral, small molecule C-terminal modulator of Hsp90. Cemdomespib is hypothesized to bind the C-terminus of Hsp90 and lead to increased transcription of cytoprotective and molecular chaperone genes including Hsp70. HSP90 modulation and HSP70 induction have the potential to reduce diabetic nerve pain. Currently, the drug is in Phase II stage of its development for the treatment of Diabetic neuropathic pain.
- LX9211: Lexicon Pharmaceuticals
LX9211 is an orally-delivered small molecule compound. The scientists identified the target of LX9211, adapter-associated kinase 1, or AAK1, in target discovery efforts based on their discovery that mice lacking AAK1 exhibited increased resistance to induced neuropathic pain in preclinical models. LX9211 is discovered within the drug discovery alliance with Bristol-Myers Squibb from which Lexicon Pharmaceuticals hold exclusive development and commercialization rights. Preclinical studies of LX9211 demonstrated central nervous system penetration and reduction in pain behavior in models of neuropathic pain without affecting opiate pathways. LX9211 has received Fast Track designation from the FDA for development in diabetic peripheral neuropathic pain. Currently, the drug is in Phase II stage of its development for the treatment of Diabetic neuropathic pain.
- AJH-2947: JMackem
AJH-2947 is a novel investigational small molecule candidate being developed by JMackem. The drug candidate are TRPV1 receptor antagonists. Presently Phase-I clinical trials in Diabetic neuropathies is going on in South Korea. AJH-2947 is administered orally. Currently, the drug is in Phase I stage of its development for the treatment of Diabetic neuropathic pain.
Learn more about Diabetic Neuropathic Pain Drugs opportunities in our groundbreaking Diabetic Neuropathic Pain Research and development projects @ Diabetic Neuropathic Pain Unmet Needs
Diabetic Neuropathic Pain pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration
- Oral
- Intravenous
- Subcutaneous
- Parenteral
- Topical
Diabetic Neuropathic Pain Products have been categorized under various Molecule types such as
- Recombinant fusion proteins
- Small molecule
- Monoclonal antibody
- Peptide
- Polymer
- Gene therapy
Discover the latest advancements in Diabetic Neuropathic Pain Treatment by visiting our website. Stay informed about how we're transforming the future of Oncology @ Diabetic Neuropathic Pain Market Drivers and Barriers, and Future Perspectives
Scope of the Diabetic Neuropathic Pain Pipeline Report
- Coverage- Global
- Diabetic Neuropathic Pain Companies- Lexicon Pharmaceuticals, Biogen, JMackem, Zhejiang Hanmai Pharmaceutical Technology Co., Ltd., Eli Lilly and Company, Lateral Pharma Pty Ltd, Tris Pharma, Inc., and others.
- Diabetic Neuropathic Pain Therapies- Incobotulinumtoxin-A 100 UNIT Injection, LX9211, JMKX000623, Pregabalin, RTA 901, HSK16149 20mg BID, and others.
- Diabetic Neuropathic Pain Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
- Diabetic Neuropathic Pain Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
For a detailed overview of our latest research findings and future plans, read the full details of Diabetic Neuropathic Pain Pipeline on our website @ Diabetic Neuropathic Pain Drugs and Companies
Table of Content
- Introduction
- Executive Summary
- Diabetic Neuropathic Pain: Overview
- Pipeline Therapeutics
- Therapeutic Assessment
- Diabetic Neuropathic Pain– DelveInsight’s Analytical Perspective
- Late Stage Products (Phase III)
- Drug Name: Company Name
- Drug profiles in the detailed report…..
- Mid Stage Products (Phase II)
- LX9211: Lexicon Pharmaceuticals
- Drug profiles in the detailed report…..
- Early Stage Products (Phase I)
- AJH-2947: JMackem
- Drug profiles in the detailed report…..
- Preclinical and Discovery Stage Products
- Drug Name: Company Name
- Drug profiles in the detailed report…..
- Inactive Products
- Diabetic Neuropathic Pain Key Companies
- Diabetic Neuropathic Pain Key Products
- Diabetic Neuropathic Pain- Unmet Needs
- Diabetic Neuropathic Pain- Market Drivers and Barriers
- Diabetic Neuropathic Pain- Future Perspectives and Conclusion
- Diabetic Neuropathic Pain Analyst Views
- Diabetic Neuropathic Pain Key Companies
- Appendix
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email:Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/
